Abstracts tagged "pulmonary fibrosis"

Abstract Number: 1654 • 2019 ACR/ARP Annual Meeting
Esophageal Dilation and Other Clinical Factors Associated with Pulmonary Function Decline in Patients with Systemic Sclerosis
Kimberly Showalter¹, Aileen Hoffmann ², Carrie Richardson ³, Kimberly Koloms ², Gerald Rouleau ², David Aaby ², Julia (Jungwha) Lee ⁴, Jane Dematte ², Rishi Agrawal ², Xiaoping Wu ⁵, Rowland Chang ⁴ and Monique Hinchcliff ⁶, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University Feinberg School of Medicine, Chicago, ³Rush University, Chicago, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵New York Presbyterian/Weill Cornell, New York, ⁶Yale University, Section of Rheumatology, Allergy and Immunology, New Haven, CT
Background/Purpose: Prior work has shown that Scl-70 positive autoantibody status and baseline c-reactive protein (CRP) are associated with more rapid pulmonary function decline in patients…
Abstract Number: 796 • 2018 ACR/ARHP Annual Meeting
Demographic and Clinical Features of Systemic Sclerosis Patients with Anti-U1RNP Antibodies: A European Scleroderma Trials and Research (EUSTAR) Analysis
Wanlong Wu^1,2, Petra Hoederath¹, Eric Hachulla³, Paolo Airò⁴, Gabriele Valentini⁵, Marco Matucci Cerinic⁶, Franco Cozzi⁷, Gabriela Riemekasten⁸, Yannick Allanore⁹, Patricia Carreira¹⁰, Suzana Jordan¹¹ and Oliver Distler¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Rheumatology, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ³Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, ⁴Rheumatology and Clinical immunology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁵Department of Clinical and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁶Division of Rheumatology, Division of Rheumatology, University of Florence, Florence, Italy, ⁷Division of Rheumatology, Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy, ⁸Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ⁹Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, ¹⁰Servicio de Reumatologia, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Anti-U1RNP antibodies can be detected in patients with systemic sclerosis (SSc). However, their prevalence and clinical correlation with organ-specific complications have not been well…
Abstract Number: 1723 • 2018 ACR/ARHP Annual Meeting
Intensified B-Cell Depletion Therapy in Progressive Systemic Sclerosis Patients: 24 Months Follow-up
Daniela Rossi¹, Irene Cecchi², Massimo Radin³, Elena Rubini⁴, Savino Sciascia⁵ and Dario Roccatello⁶, ¹Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy
Background/Purpose:Systemic sclerosis (SSc) is a connective tissue autoimmune disease with systemic involvement and a serious medical condition with a high rate of mortality, especially due…
Abstract Number: 1742 • 2018 ACR/ARHP Annual Meeting
Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis
Svetlana I. Nihtyanova¹, Alper Sari², Anna Leslie³, Voon H. Ong⁴ and Christopher P. Denton⁵, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Division of Medicine, University College London, London, United Kingdom, ⁵University College London, London, United Kingdom
Background/Purpose: Pulmonary fibrosis (PF) is a leading cause of disease-related death in SSc patients. Some studies suggest that the timing of PF development differs between…
Abstract Number: 732 • 2017 ACR/ARHP Annual Meeting
Progression of Skin Fibrosis Is Associated with Decline in Lung Function in Patients with Diffuse Cutaneous Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis
Wanlong Wu¹, Suzana Jordan², Nicole Graf³, Janethe Pena⁴, John Curram⁵, Yannick Allanore⁶, Marco Matucci-Cerinic⁷, Janet E. Pope⁸, Christopher Denton⁹, Dinesh Khanna¹⁰ and Oliver Distler¹, ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Graf Biostatistics, Winterthur, Switzerland, ⁴Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ, ⁵Bayer Plc, Newbury, United Kingdom, ⁶Department of Rheumatology, Cochin Hospital, Paris Descartes University, Paris, France, ⁷Dept of Medicine/Div of Rheum, University of Florence, Florence, Italy, ⁸Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁹Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ¹⁰Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Previously, we have identified short disease duration (≤15 months) and low baseline modified Rodnan skin score (mRSS) (≤22/51) as independent predictors of progressive skin…
Abstract Number: 2983 • 2017 ACR/ARHP Annual Meeting
Predictors for Disease Worsening Defined By Organ Failure in Diffuse Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis
Mike Oliver Becker¹, Nicole Graf², Rafael Sauter³, Yannick Allanore⁴, John Curram⁵, Christopher Denton⁶, Dinesh Khanna⁷, Marco Matucci-Cerinic⁸, Janethe Pena⁹, Janet E. Pope¹⁰ and Oliver Distler¹, ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Graf Biostatistics, Winterthur, Switzerland, ³Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ⁴Department of Rheumatology, Cochin Hospital, Paris Descartes University, Paris, France, ⁵Bayer Plc, Newbury, United Kingdom, ⁶Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ⁷University of Michigan, Ann Arbor, MI, ⁸Dept of Medicine/Div of Rheum, University of Florence, Florence, Italy, ⁹Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ, ¹⁰Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada
Background/Purpose: Mortality and worsening of organ function would be desirable endpoints for clinical trials in systemic sclerosis (SSc). However, these events are relatively rare, making…
Abstract Number: 1889 • 2015 ACR/ARHP Annual Meeting
Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease
Natalie K. Kozij¹, John T. Granton², Philip E. Silkoff³, John Thenganatt⁴, Shobha Chakravorty⁴ and Sindhu R. Johnson⁵, ¹Department of Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada., Toronto, ON, Canada, ²Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Temple University, Philadelphia, PA, ⁴Respirology, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ⁵Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: We evaluated the ability of alveolar and conducting airway nitric oxide (NO) to discriminate between systemic sclerosis (SSc) with and without lung involvement, idiopathic…
Abstract Number: 1919 • 2015 ACR/ARHP Annual Meeting
Genetic Deletion of Toll-like Receptor 4 (Tlr4) Abrogates TGF-β1-Induced Endothelial-to-Mesenchymal Transition (EndoMT) in Murine Pulmonary Endothelial Cells
Peter J. Wermuth¹ and Sergio A. Jimenez², ¹Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, ²Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease of unknown etiology whose pathogenesis involves the regulation of a diverse range of molecular pathways. The…
Abstract Number: 3002 • 2015 ACR/ARHP Annual Meeting
The Regulatory Role of Gammadelta T Cells in Bleomycin-Induced Pulmonary Fibrosis
Seiji Segawa¹, Daisuke Goto², Akira Iizuka³, Masahiro Yokosawa³, Shunta Kaneko³, Yuya Kondo³, Isao Matsumoto³ and Takayuki Sumida³, ¹Division of Clinical Immunology, Doctoral Program in Clinical Sciences,, University of Tsukuba, Tsukuba, Japan, ²Division of Clinical Immunology, Doctoral Program in Clinical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Interstitial pneumonia (IP) is a chronic progressive interstitial lung disease associated with high mortality and poor prognosis. However, the exact mechanism of IP remains…
Abstract Number: 1797 • 2014 ACR/ARHP Annual Meeting
One-Year Survival of Adults with Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study
Elana J. Bernstein¹, Eric R. Peterson², Joan M. Bathon² and David J. Lederer², ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Medicine, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Lung transplantation is a potentially life-saving treatment for patients with systemic sclerosis (SSc) who have developed end-stage lung disease due to interstitial lung disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].